Despite first director decisions, Arthrex reviews remain clouded in uncertainty

Despite first director decisions, Arthrex reviews remain clouded in uncertainty

The jury is still out on whether the interim USPTO measures represent a meaningful process or a rubber stamping exercise, while some worry the agency’s acting head Drew Hirshfeld lacks standing to issue them

Unlock unlimited access to all IAM content